Illinois Municipal Retirement Fund Sells 2,225 Shares of Amgen Inc. $AMGN

Illinois Municipal Retirement Fund lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 25.1% in the 3rd quarter, Holdings Channel.com reports. The fund owned 6,648 shares of the medical research company’s stock after selling 2,225 shares during the period. Illinois Municipal Retirement Fund’s holdings in Amgen were worth $1,876,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of AMGN. Brighton Jones LLC increased its position in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 114 shares during the period. Signature Estate & Investment Advisors LLC boosted its stake in shares of Amgen by 11.5% during the second quarter. Signature Estate & Investment Advisors LLC now owns 6,216 shares of the medical research company’s stock valued at $1,736,000 after purchasing an additional 640 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Amgen during the 2nd quarter valued at $11,501,000. Finally, Cidel Asset Management Inc. raised its stake in shares of Amgen by 3.1% during the second quarter. Cidel Asset Management Inc. now owns 3,242 shares of the medical research company’s stock valued at $905,000 after acquiring an additional 99 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of research analyst reports. Royal Bank Of Canada raised their price target on Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 4th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Guggenheim upped their target price on shares of Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Morgan Stanley boosted their price target on Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. Finally, Mizuho upped their target price on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $354.04.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares of the company’s stock, valued at $2,436,703.50. This trade represents a 30.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.69% of the stock is owned by insiders.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $369.19 on Tuesday. The firm has a market cap of $198.80 billion, a price-to-earnings ratio of 25.94, a P/E/G ratio of 3.78 and a beta of 0.46. The firm has a fifty day moving average price of $338.43 and a 200 day moving average price of $314.29. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $385.12. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the previous year, the firm posted $5.31 EPS. Amgen’s revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.7%. This is an increase from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.